Prochaines mises à jour
pour 2026-2027

octobre 2026

Quick Take Vol. 93

Scott R. Beach, M.D., Harvard Medical School
Inclus dans les adhésions Silver ou Silver extended.

Substitution des antipsychotiques en pratique clinique

Brian Miller, M.D., Ph.D., M.P.H., Medical College of Georgia Augusta University
Inclus dans les adhésions Bronze, Silver, Bronze extended ou Silver extended.
novembre 2026

Guide du brexpiprazole : pharmacologie, indications, posologie et effets indésirables

Sebastián Malleza, M.D., Psychopharmacology Institute
Inclus dans les adhésions Silver ou Silver extended.

Prise en charge du TDAH complexe – Interview

To Be Announced
Inclus dans les adhésions Silver ou Silver extended.

Quick Take Vol. 94

Scott R. Beach, M.D., Harvard Medical School
Inclus dans les adhésions Silver ou Silver extended.

Pharmacothérapie du trouble lié à l'usage du cannabis

Joao P. De Aquino, M.D., Yale University School of Medicine
Inclus dans les adhésions Bronze, Silver, Bronze extended ou Silver extended.
décembre 2026

Guide de l'aripiprazole : pharmacologie, indications, posologie et effets indésirables

Sebastián Malleza, M.D., Psychopharmacology Institute
Inclus dans les adhésions Silver ou Silver extended.

Quick Take Vol. 95

Scott R. Beach, M.D., Harvard Medical School
Inclus dans les adhésions Silver ou Silver extended.

Citalopram et escitalopram : résumé des principales différences et similitudes (mise à jour 2026)

Sebastián Malleza, M.D., Psychopharmacology Institute
Inclus dans les adhésions Silver ou Silver extended.
janvier 2027

L'algorithme de psychopharmacologie pour la dépression psychotique

David Osser, M.D., Harvard Medical School
Inclus dans les adhésions Bronze, Silver, Bronze extended ou Silver extended.

Guide du lithium : pharmacologie, indications, posologie et effets indésirables

Sebastián Malleza, M.D., Psychopharmacology Institute
Inclus dans les adhésions Silver ou Silver extended.

Quick Take Vol. 96

Scott R. Beach, M.D., Harvard Medical School
Inclus dans les adhésions Silver ou Silver extended.

Psychopharmacologie chez les adultes présentant une déficience intellectuelle : quand prescrire, quand arrêter

To Be Announced
Inclus dans les adhésions Silver ou Silver extended.
février 2027

Interactions médicamenteuses en psychopharmacologie

To Be Announced
Inclus dans les adhésions Bronze, Silver, Bronze extended ou Silver extended.

Guide de l'atomoxétine : pharmacologie, indications, posologie et effets indésirables

Sebastián Malleza, M.D., Psychopharmacology Institute
Inclus dans les adhésions Silver ou Silver extended.

Quick Take Vol. 97

Scott R. Beach, M.D., Harvard Medical School
Inclus dans les adhésions Silver ou Silver extended.

Guide pratique sur la fluvoxamine : pharmacologie, indications, posologie et effets indésirables (mise à jour 2027)

Sebastián Malleza, M.D., Psychopharmacology Institute
Inclus dans les adhésions Silver ou Silver extended.
mars 2027

Pharmacothérapie des troubles liés à l'usage de substances pendant la grossesse

To Be Announced
Inclus dans les adhésions Bronze, Silver, Bronze extended ou Silver extended.

Guide du méthylphénidate : pharmacologie, indications, posologie et effets indésirables

Sebastián Malleza, M.D., Psychopharmacology Institute
Inclus dans les adhésions Silver ou Silver extended.

Psychopharmacologie de la prise de poids et de l'obésité

To Be Announced
Inclus dans les adhésions Silver ou Silver extended.
avril 2027

Quick Take Vol. 98

Oliver Freudenreich, M.D., F.A.C.L.P., Massachusetts General Hospital – Harvard Medical School
Inclus dans les adhésions Silver ou Silver extended.

Trop de doses, trop de médicaments : plafonds posologiques et polymédication en psychiatrie

Christopher Keary, M.D., Harvard Medical School & Lurie Center for Autism at Massachusetts General Hospital for Children
Inclus dans les adhésions Bronze, Silver, Bronze extended ou Silver extended.

Guide des amphétamines : pharmacologie, indications, recommandations posologiques et effets indésirables

Sebastián Malleza, M.D., Psychopharmacology Institute
Inclus dans les adhésions Silver ou Silver extended.

Guide sur la venlafaxine : pharmacologie, indications, posologie et effets indésirables (mise à jour 2027)

Sebastián Malleza, M.D., Psychopharmacology Institute
Inclus dans les adhésions Silver ou Silver extended.
mai 2027

Psychopharmacologie de l'autisme

Christopher Keary, M.D., Harvard Medical School & Lurie Center for Autism at Massachusetts General Hospital for Children
Inclus dans les adhésions Bronze, Silver, Bronze extended ou Silver extended.

Quick Take Vol. 99

Oliver Freudenreich, M.D., F.A.C.L.P., Massachusetts General Hospital – Harvard Medical School
Inclus dans les adhésions Silver ou Silver extended.

Médicaments du TDAH : un guide complet des formulations

Sebastián Malleza, M.D., Psychopharmacology Institute
Inclus dans les adhésions Silver ou Silver extended.
juin 2027

Le trouble bipolaire durant la période périnatale

To Be Announced
Inclus dans les adhésions Bronze, Silver, Bronze extended ou Silver extended.

Quick Take Vol. 100

Scott R. Beach, M.D., Harvard Medical School
Inclus dans les adhésions Silver ou Silver extended.
juillet 2027

Quick Take Vol. 101

Scott R. Beach, M.D., Harvard Medical School
Inclus dans les adhésions Silver ou Silver extended.

Guide de la desvenlafaxine : pharmacologie, indications, posologie et effets indésirables (mise à jour de 2027)

Sebastián Malleza, M.D., Psychopharmacology Institute
Inclus dans les adhésions Silver ou Silver extended.
août 2027

Quick Take Vol. 102

Scott R. Beach, M.D., Harvard Medical School
Inclus dans les adhésions Silver ou Silver extended.
septembre 2027

Quick Take Vol. 103

Scott R. Beach, M.D., Harvard Medical School
Inclus dans les adhésions Silver ou Silver extended.

Guide de la duloxétine : pharmacologie, indications, posologie et effets indésirables (Mise à jour de 2027)

Sebastián Malleza, M.D., Psychopharmacology Institute
Inclus dans les adhésions Silver ou Silver extended.
octobre 2027

CME Information

Physicians – CME Accreditation Statement

The activities below have been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Medical Academy LLC and the Psychopharmacology Institute. Medical Academy LLC is accredited by the ACCME to provide continuing medical education for physicians.

Medical Academy, LLC designates each enduring material for the number of AMA PRA Category 1 Credits™ listed below. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Download Accreditation Information (PDF)

Nursing professionals – CME Accreditation Statement

The activities below have been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Medical Academy LLC and the Psychopharmacology Institute. Medical Academy LLC is accredited by the ACCME to provide continuing medical education for physicians.

Medical Academy, LLC designates each enduring material for the number of AMA PRA Category 1 Credits™ listed below. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

The ANCC accepts AMA PRA Category 1 Credit(s)™ as Contact Hours, under this calculation: 1 CME = 1 Contact Hour. 

All of our content is psychopharmacology, so the pharmacology hours shown on your certificate match the credits awarded for that activity. Your certificate states them on their own line, separately from the credit designation statement.

This applies to APRN pharmacology renewal as well. Boards of nursing define pharmacology CE in their own way, so please confirm with your board that this is the documentation they expect.

Download Accreditation Information (PDF)

Physician assistants – CME Accreditation Statement

The activities below have been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Medical Academy LLC and the Psychopharmacology Institute. Medical Academy LLC is accredited by the ACCME to provide continuing medical education for physicians.

Medical Academy, LLC designates each enduring material for the number of AMA PRA Category 1 Credits™ listed below. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

The NCCPA accepts AMA PRA Category 1 Credit™ from providers accredited by the ACCME toward PA certification maintenance. Requirements are set by the NCCPA, so please confirm with them what your current cycle requires.

Download Accreditation Information (PDF)

Physicians outside the United States – CME Accreditation Statement

AMA PRA Category 1 Credit™ may be awarded to any physician, whether or not they are licensed in the United States. The requirements are the same.

The American Medical Association has an agreement of mutual recognition of Continuing Medical Education (CME) credits with the European Union of Medical Specialists (UEMS), the accreditation body for European countries. Physicians interested in converting AMA PRA Category 1 Credit™ to UEMS-European Accreditation Council for Continuing Medical Education CME credits (ECMEC®s) should contact the UEMS at mutualrecognition@uems.eu.

Whether these credits count toward your own national continuing education requirement is decided by your national medical chamber or society, and the rules differ from country to country. We recommend confirming with them before relying on the credits for a licensing or recertification requirement.

Self Assessment for MOC – Accreditation Statement
  • Psychopharmacology Institute Self-Assessment Program 2026

Dates: April 1, 2026 – April 1, 2029

The American Board of Psychiatry and Neurology has reviewed the Psychopharmacology Institute Self-Assessment Program 2026 and has approved this activity as part of a comprehensive Self-Assessment activity, which is mandated by the ABMS as a necessary component of Continuing Certification.

  • Psychopharmacology Institute Self-Assessment Program 2025

Dates: April 1, 2025 – April 1, 2028

The American Board of Psychiatry and Neurology has reviewed the Psychopharmacology Institute Self-Assessment Program 2025 and has approved this activity as part of a comprehensive Self-Assessment activity, which is mandated by the ABMS as a necessary component of Continuing Certification.

  • Psychopharmacology Institute Self-Assessment Program 2024

Dates: April 1, 2024 – April 1, 2027

The American Board of Psychiatry and Neurology has reviewed the Psychopharmacology Institute Self-Assessment Program 2024 and has approved this activity as part of a comprehensive Self-Assessment activity, which is mandated by the ABMS as a necessary component of Continuing Certification.